881900-17-0

Upstream product

• 67-56-1 methanol 
• 116209-30-4 4-bromo-2-mercaptobenzoic acid 
• 20776-50-5 2-amino-4-bromobenzoic acid 
• 135484-83-2 2-amino-4-bromo-benzoic acid methyl ester 
• 179232-29-2 methyl 4-bromo-2-fluorobenzoate 

Downstream Products

• 881900-18-1 methyl 4-bromo-2-[(cyanomethyl)thio]benzoate 
• 881900-19-2 6-bromo-3-hydroxy-1-benzothiophene-2-carbonitrile 
• 881900-20-5 3-hydroxy-6-phenyl-1-benzothiophene-2-carbonitrile 
• 881900-21-6 2-[(2-cyano-6-phenyl-1-benzothien-3-yl)oxy]acetamide 
• 881899-92-9 3-amino-6-phenyl[1]benzothieno[3,2-b]furan-2-carboxamide 

Relevant academic research and scientific papers

Benzimidazole or azabenzimidazole -6 - carboxylic acid compound and application thereof

The invention discloses benzimidazole or azabenzimidazole -6 - carboxylic acid compound and application thereof, wherein the benzimidazole or azabenzimidazole -6 - carboxylic acid compound has the structure shown in the formula (I). The benzimidazole or a

PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII

The present invention provides compounds of formula (I) wherein X1 to X8 and R1 to R8 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by Acinetobacter baumannii.

Synthesis and structure activity relationship studies of benzothieno[3,2-b]furan derivatives as a novel class of IKKβ inhibitors

As a novel class of IKKβ inhibitors, a series of tricyclic furan derivatives was designed and synthesized based on the structure of known thiophene IKKβ inhibitors. Among the various fused furan derivatives synthesized, a benzothieno[3,2-b]furan derivative 13a displayed potent inhibitory activity towards IKKβ in enzymatic and cellular assays. The potent inhibitory activity originates from an intramolecular non-bonded S...O interaction which was confirmed by the X-ray structure of JNK3 with 16k. The introduction of further substituents on the core structure led to the discovery of the 6-alkoxy derivatives, which possessed a comparable IKKβ inhibitory activity to 13a and an improved metabolic stability. Among these, appropriately lipophilic compounds 16a, h, i, and 13g (logD>2) were found to possess good oral bioavailability.